MedTrace Logo

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

NCT00913133 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2013-01-10

Study results available
· View outcomes & findings →

Summary

The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.

Conditions

Interventions

DRUG

Desirudin

Desirudin SC 15mg q12h

Sponsors & Collaborators

  • Canyon Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Dawn Bell, PharmD · Canyon Pharmaceuticals, Inc.

  • Jerrold Levy, MD, FAHA · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913133 on ClinicalTrials.gov